KR20230104151A - 아세트아미도-페닐테트라졸 유도체 및 그의 사용 방법 - Google Patents
아세트아미도-페닐테트라졸 유도체 및 그의 사용 방법 Download PDFInfo
- Publication number
- KR20230104151A KR20230104151A KR1020237015140A KR20237015140A KR20230104151A KR 20230104151 A KR20230104151 A KR 20230104151A KR 1020237015140 A KR1020237015140 A KR 1020237015140A KR 20237015140 A KR20237015140 A KR 20237015140A KR 20230104151 A KR20230104151 A KR 20230104151A
- Authority
- KR
- South Korea
- Prior art keywords
- heteroatoms selected
- alkyl
- membered
- aryl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063088788P | 2020-10-07 | 2020-10-07 | |
| US63/088,788 | 2020-10-07 | ||
| PCT/US2021/053937 WO2022076663A1 (en) | 2020-10-07 | 2021-10-07 | Acetamido-phenyltetrazole derivatives and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230104151A true KR20230104151A (ko) | 2023-07-07 |
Family
ID=78483546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237015140A Pending KR20230104151A (ko) | 2020-10-07 | 2021-10-07 | 아세트아미도-페닐테트라졸 유도체 및 그의 사용 방법 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11739089B2 (enExample) |
| EP (1) | EP4225747A1 (enExample) |
| JP (2) | JP7823036B2 (enExample) |
| KR (1) | KR20230104151A (enExample) |
| CN (1) | CN116964044B (enExample) |
| AU (1) | AU2021358074A1 (enExample) |
| CA (1) | CA3194694A1 (enExample) |
| IL (1) | IL301516A (enExample) |
| MX (1) | MX2023003933A (enExample) |
| TW (1) | TWI900672B (enExample) |
| WO (1) | WO2022076663A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016057931A1 (en) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| CN110312130B (zh) * | 2019-06-25 | 2021-10-15 | 浙江大华技术股份有限公司 | 基于三角模式的帧间预测、视频编码方法及设备 |
| WO2022076663A1 (en) | 2020-10-07 | 2022-04-14 | Athenex, Inc. | Acetamido-phenyltetrazole derivatives and methods of using the same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5663179A (en) | 1992-07-10 | 1997-09-02 | Laboratoires Glaxo Sa | Certain isoquinoline derivatives having anti-tumor properties |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| GB9717576D0 (en) | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
| KR100557093B1 (ko) | 2003-10-07 | 2006-03-03 | 한미약품 주식회사 | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 |
| KR101466245B1 (ko) * | 2010-01-15 | 2014-12-01 | 한미사이언스 주식회사 | 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물 |
| KR101986683B1 (ko) * | 2012-12-13 | 2019-06-10 | 한미약품 주식회사 | 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체 |
| WO2015152433A1 (en) | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
| KR102293907B1 (ko) | 2015-06-30 | 2021-08-26 | 한미약품 주식회사 | 이리노테칸 함유 경구용 고형제제 및 그 제조방법 |
| TWI715636B (zh) | 2015-09-30 | 2021-01-11 | 香港商慧源香港創新有限公司 | 口服紫杉烷組合物及方法 |
| TWI833710B (zh) | 2017-10-06 | 2024-03-01 | 香港商慧源香港創新有限公司 | 高單位含量口服型紫杉烷組合物及方法 |
| WO2022076663A1 (en) | 2020-10-07 | 2022-04-14 | Athenex, Inc. | Acetamido-phenyltetrazole derivatives and methods of using the same |
-
2021
- 2021-10-07 WO PCT/US2021/053937 patent/WO2022076663A1/en not_active Ceased
- 2021-10-07 MX MX2023003933A patent/MX2023003933A/es unknown
- 2021-10-07 US US17/495,935 patent/US11739089B2/en active Active
- 2021-10-07 CA CA3194694A patent/CA3194694A1/en active Pending
- 2021-10-07 IL IL301516A patent/IL301516A/en unknown
- 2021-10-07 CN CN202180079852.2A patent/CN116964044B/zh active Active
- 2021-10-07 AU AU2021358074A patent/AU2021358074A1/en active Pending
- 2021-10-07 TW TW110137339A patent/TWI900672B/zh active
- 2021-10-07 JP JP2023521299A patent/JP7823036B2/ja active Active
- 2021-10-07 KR KR1020237015140A patent/KR20230104151A/ko active Pending
- 2021-10-07 EP EP21801761.4A patent/EP4225747A1/en active Pending
-
2026
- 2026-02-18 JP JP2026024155A patent/JP2026090442A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023544615A (ja) | 2023-10-24 |
| CN116964044B (zh) | 2026-03-06 |
| US11739089B2 (en) | 2023-08-29 |
| AU2021358074A1 (en) | 2023-04-27 |
| MX2023003933A (es) | 2023-07-05 |
| CN116964044A (zh) | 2023-10-27 |
| IL301516A (en) | 2023-05-01 |
| CA3194694A1 (en) | 2022-04-14 |
| US20220106312A1 (en) | 2022-04-07 |
| TWI900672B (zh) | 2025-10-11 |
| TW202233593A (zh) | 2022-09-01 |
| JP7823036B2 (ja) | 2026-03-03 |
| EP4225747A1 (en) | 2023-08-16 |
| JP2026090442A (ja) | 2026-06-02 |
| WO2022076663A1 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109665968B (zh) | 并环化合物及其制备方法和用途 | |
| CN102264707B (zh) | 双环型杂环化合物 | |
| RU2734760C2 (ru) | Противоинфекционные соединения | |
| AU2009260503B2 (en) | Wnt protein signalling inhibitors | |
| TWI900672B (zh) | 乙醯胺基－苯基四唑衍生物及其使用方法 | |
| AU2020271268B2 (en) | Inhibitors of Notch signalling pathway and use thereof in treatment of cancers | |
| KR20220141331A (ko) | P2x3 조정제 | |
| JP2018535273A (ja) | メタロ−ベータ−ラクタマーゼの阻害剤 | |
| JP2022544700A (ja) | 筋萎縮性側索硬化症および関連障害の治療のためにｔｄｐ－４３に結合する分子 | |
| WO2024026423A1 (en) | Substituted quinoline derivatives as pi3k inhibitors | |
| AU2013276165A1 (en) | Tricyclic compounds as KAT II inhibitors | |
| CN116940562B (zh) | 乙酰胺基-苯基苯甲酰胺衍生物及其使用方法 | |
| WO2022199045A1 (zh) | 双环杂环fgfr4抑制剂，包含其的药物组合物和制剂，及其应用 | |
| HK40102895A (en) | Acetamido-phenylbenzamide derivatives and methods of using the same | |
| CN110724076A (zh) | 对芳基二甲酰胺类化合物、包含其的药物组合物、其制备方法及其用途 | |
| CN117777132A (zh) | α-N-芳基氨基酰胺及其制备方法和药用用途 | |
| AU687414B2 (en) | Piperidinyl substituted methanoanthracenes as D1/D2-antagonists and 5HT2-serotanin-antagonists | |
| TW202334097A (zh) | 用於治療癌症之苯并【ｈ】喹唑啉－４－胺衍生物 | |
| CN118894859A (zh) | DNA聚合酶θ抑制剂、其中间体、其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |